The RNA editing enzyme ADAR2 restricts L1 mobility

RNA Biol. 2021 Oct 15;18(sup1):75-87. doi: 10.1080/15476286.2021.1940020. Epub 2021 Jul 5.

Abstract

Adenosine deaminases acting on RNA (ADARs) are enzymes that convert adenosines to inosines in double-stranded RNAs (RNA editing A-to-I). ADAR1 and ADAR2 were previously reported as HIV-1 proviral factors. The aim of this study was to investigate the composition of the ADAR2 ribonucleoprotein complex during HIV-1 expression. By using a dual-tag affinity purification procedure in cells expressing HIV-1 followed by mass spectrometry analysis, we identified 10 non-ribosomal ADAR2-interacting factors. A significant fraction of these proteins was previously found associated to the Long INterspersed Element 1 (LINE1 or L1) ribonucleoparticles and to regulate the life cycle of L1 retrotransposons. Considering that we previously demonstrated that ADAR1 is an inhibitor of LINE-1 retrotransposon activity, we investigated whether also ADAR2 played a similar function. To reach this goal, we performed specific cell culture retrotransposition assays in cells overexpressing or ablated for ADAR2. These experiments unveil a novel function of ADAR2 as suppressor of L1 retrotransposition. Furthermore, we showed that ADAR2 binds the basal L1 RNP complex.Overall, these data support the role of ADAR2 as regulator of L1 life cycle.

Keywords: ADAR2; LINE-1; RNA editing; double-stranded RNA (dsRNA); retrotransposons.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine Deaminase / genetics
  • Adenosine Deaminase / metabolism*
  • HEK293 Cells
  • HeLa Cells
  • Humans
  • Long Interspersed Nucleotide Elements*
  • RNA Editing*
  • RNA-Binding Proteins / genetics
  • RNA-Binding Proteins / metabolism*

Substances

  • RNA-Binding Proteins
  • ADARB1 protein, human
  • Adenosine Deaminase

Grants and funding

This work was supported by grants of the United Leukodystrophy Foundation to AM, Ministry for Health of Italy (Ricerca Corrente) and Sapienza University of Rome (RG11916B6A9C42C7) to MT and Italian Ministry of Health (Ricerca Finalizzata RF-2016-02363642 and Ricerca Corrente co-funded by the Italian 5 × 1000) to MD.